Sjogren's syndrome - Pipeline Insight, 2021

DelveInsight’s, “Sjogren’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Sjogren’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Sjogren’s syndrome Understanding
Sjogren’s syndrome: Overview
Sjogren’s syndrome is an autoimmune condition that can occur at any age, but is most common in older women. Many patients develop Sjogren’s syndrome as a complication of another autoimmune disease, such as rheumatoid arthritis or lupus. Symptoms vary in type and intensity, but many people with Sjogren’s are able to live normal lives.
Most of the treatment for Sjogren’s syndrome is aimed at relieving symptoms of dry eyes and mouth and preventing and treating long-term complications such as infection and dental disease. Treatments often do not completely eliminate the symptoms of dryness. Most patients with Sjogren’s syndrome remain healthy, but some rare complications have been described, including an increased risk for cancer of the lymph glands (lymphoma). Thus, regular medical care and follow up is important for all patients.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Sjogren’s syndrome R&D. The therapies under development are focused on novel approaches for Sjogren’s syndrome.
Sjogren’s syndrome Emerging Drugs Chapters
This segment of the Sjogren’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sjogren’s syndrome Emerging Drugs
• HZN-4920: Horizon Therapeutics
HZN-4920 is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. It is currently in Phase II stage of development for the treatment of Sjogren’s syndrome and is being developed by Horizon Therapeutics.
• Iscalimab: Novartis
Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. It is currently in Phase II stage of development for the treatment of Sjogren’s syndrome and is being developed by Novartis.
Further product details are provided in the report??..
Sjogren’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Sjogren’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Sjogren’s syndrome
There are approx. 20+ key companies which are developing the Sjogren’s syndrome. The companies which have their Sjogren’s syndrome drug candidates in the most advanced stage, i.e. Phase II include, Horizon Therapeutics.
• Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Sjogren’s syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sjogren’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sjogren’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sjogren’s syndrome drugs.

Sjogren’s syndrome Report Insights

• 
  • Sjogren’s syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
  Sjogren’s syndrome Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
  
  Key Questions
  Current Scenario and Emerging Therapies:
  • How many companies are developing Sjogren’s syndrome drugs?
  • How many Sjogren’s syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Sjogren’s syndrome?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sjogren’s syndrome therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Sjogren’s syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?
  Key Players
  • Horizon Therapeutics
  • Novartis
  • Galapagos
  • Sanofi
  • Resolve Therapeutics
  • Bristol-Myers Squibb
  • Cytodyn
  • MeiraGTx
  • Alpine Immune Sciences
  • Servier
  Key Products
  • HZN-4920
  • Iscalimab
  • LOU-064
  • GLPG3970
  • SAR441344
  • RSLV-132
  • BMS-986325
  • AAV-AQP1
  • ALPN-303
  • S95011